Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Lupus nephritis

(2020) Hans-Joachim Anders et al.   Nature Reviews Disease Primers

2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis

(2020) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies

(2020) Chi Chiu Mok et al.   LUPUS

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

(2020) Richard Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glomerular Hematuria: Cause or Consequence of Renal Inflammation?

(2019) Juan Antonio Moreno et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways

(2019) Evan Der et al.   NATURE IMMUNOLOGY

Associated clinical factors for serious infections in patients with systemic lupus erythematosus

(2019) Ju-Yang Jung et al.   Scientific Reports

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

(2019) Eric F. Morand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucocorticoids and antimalarials in systemic lupus erythematosus

(2018) Amaia Ugarte et al.   CURRENT OPINION IN RHEUMATOLOGY

A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis

(2018) Hong Wang   Archives of Rheumatology

Systemic lupus erythematosus: Diagnosis and clinical management

(2018) Andrea Fava et al.   JOURNAL OF AUTOIMMUNITY

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

(2018) Brad H. Rovin et al.   KIDNEY INTERNATIONAL

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis

(2016) J. A. Singh et al.   JOURNAL OF RHEUMATOLOGY

Hurdles to the introduction of new therapies for immune-mediated kidney diseases

(2016) Hans-Joachim Anders et al.   Nature Reviews Nephrology

Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis

(2016) Maria G. Tektonidou et al.   Arthritis & Rheumatology

The frequency and outcome of lupus nephritis: results from an international inception cohort study

(2015) John G. Hanly et al.   RHEUMATOLOGY

Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials

(2015) Kristin M Corapi et al.   ARTHRITIS RESEARCH & THERAPY

Lupus Nephritis and End-stage Kidney Disease

(2013) Natallia Maroz et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

(2012) Yihong Yao et al.   ARTHRITIS RESEARCH & THERAPY

Proteinuria: detection and role in native renal disease progression

(2011) Jose Luis Gorriz et al.   Transplantation Reviews